S Abo1,2, D Ritchie3, L Denehy4, Y Panek-Hudson5, L Irving6, C L Granger7,4. 1. Division of Allied Health (Physiotherapy), Royal Melbourne Hospital, Parkville, VIC, 3052, Australia. shazasandra.abo@mh.org.au. 2. Department of Physiotherapy, The University of Melbourne, Parkville, VIC, 3052, Australia. shazasandra.abo@mh.org.au. 3. Department of Clinical Haematology and Bone Marrow Transplant, Royal Melbourne Hospital, Parkville, VIC, 3052, Australia. 4. Department of Physiotherapy, The University of Melbourne, Parkville, VIC, 3052, Australia. 5. Haematology Service, Peter MacCallum Cancer Centre, Parkville, VIC, 3052, Australia. 6. Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Parkville, VIC, 3052, Australia. 7. Division of Allied Health (Physiotherapy), Royal Melbourne Hospital, Parkville, VIC, 3052, Australia.
Abstract
PURPOSE: The aims of this study are to investigate the feasibility of an exercise program commencing 60 days following allogeneic stem cell transplantation (alloSCT), to investigate changes in physical function and health-related quality of life (HRQoL) in patients from pre- to post-alloSCT and to explore changes in patient outcomes before and after the program. METHODS: This study is a single site, prospective case series including 43 adults undergoing alloSCT. The intervention was an 8-week outpatient and home-based exercise and education program. Outcomes included feasibility (consent, attendance, compliance and completion rates), functional exercise capacity (incremental shuttle walk test), muscle strength (hand-held dynamometry), self-efficacy for physical activity (Physical Activity Assessment Inventory) and HRQoL (Functional Assessment of Cancer Therapy-Bone Marrow Transplant). Outcomes were measured pre-alloSCT, 60 days post-alloSCT (pre-intervention) and 100 days post-alloSCT (post-intervention). RESULTS: The consent rate was 93%. From baseline to 60 days post-alloSCT, there was significant decline in functional exercise capacity (mean difference 224 m, 95% CI 153-295, p < 0.0005), self-efficacy for physical activity (294 points, 95% CI 136-452, p = 0.001) and HRQoL (15 points, 95% CI 8-21, p < 0.0005). Ten participants did not commence the exercise program due to death (n = 5), illness (n = 1) or cancellation of alloSCT (n = 4). The intervention was feasible in those not affected by major medical complications or death. No adverse events occurred. From pre- to post-intervention, there was significant improvement in functional exercise capacity (p = 0.001) and HRQoL (p = 0.001). CONCLUSIONS:AlloSCT results in significant decline in functional exercise capacity, self-efficacy for physical activity and HRQoL, which may be improved through an exercise program. This pilot demonstrated safety, feasibility and high patient interest. Further randomised research is required.
RCT Entities:
PURPOSE: The aims of this study are to investigate the feasibility of an exercise program commencing 60 days following allogeneic stem cell transplantation (alloSCT), to investigate changes in physical function and health-related quality of life (HRQoL) in patients from pre- to post-alloSCT and to explore changes in patient outcomes before and after the program. METHODS: This study is a single site, prospective case series including 43 adults undergoing alloSCT. The intervention was an 8-week outpatient and home-based exercise and education program. Outcomes included feasibility (consent, attendance, compliance and completion rates), functional exercise capacity (incremental shuttle walk test), muscle strength (hand-held dynamometry), self-efficacy for physical activity (Physical Activity Assessment Inventory) and HRQoL (Functional Assessment of Cancer Therapy-Bone Marrow Transplant). Outcomes were measured pre-alloSCT, 60 days post-alloSCT (pre-intervention) and 100 days post-alloSCT (post-intervention). RESULTS: The consent rate was 93%. From baseline to 60 days post-alloSCT, there was significant decline in functional exercise capacity (mean difference 224 m, 95% CI 153-295, p < 0.0005), self-efficacy for physical activity (294 points, 95% CI 136-452, p = 0.001) and HRQoL (15 points, 95% CI 8-21, p < 0.0005). Ten participants did not commence the exercise program due to death (n = 5), illness (n = 1) or cancellation of alloSCT (n = 4). The intervention was feasible in those not affected by major medical complications or death. No adverse events occurred. From pre- to post-intervention, there was significant improvement in functional exercise capacity (p = 0.001) and HRQoL (p = 0.001). CONCLUSIONS: AlloSCT results in significant decline in functional exercise capacity, self-efficacy for physical activity and HRQoL, which may be improved through an exercise program. This pilot demonstrated safety, feasibility and high patient interest. Further randomised research is required.
Authors: Verônica F Parreira; Tania Janaudis-Ferreira; Rachel A Evans; Sunita Mathur; Roger S Goldstein; Dina Brooks Journal: Chest Date: 2014-06 Impact factor: 9.410
Authors: John R Wingard; William A Wood; Michael Martens; Jennifer Le-Rademacher; Brent Logan; Jennifer M Knight; Paul B Jacobsen; Heather Jim; Navneet S Majhail; Karen Syrjala; J Douglas Rizzo; Stephanie J Lee Journal: Biol Blood Marrow Transplant Date: 2016-10-11 Impact factor: 5.742
Authors: J Wiskemann; R Kuehl; P Dreger; R Schwerdtfeger; G Huber; C M Ulrich; D Jaeger; M Bohus Journal: Bone Marrow Transplant Date: 2013-12-09 Impact factor: 5.483
Authors: Amy M Dennett; Casey L Peiris; Nora Shields; Luke A Prendergast; Nicholas F Taylor Journal: J Physiother Date: 2016-03-17 Impact factor: 7.000
Authors: Daniel Y T Fong; Judy W C Ho; Bryant P H Hui; Antoinette M Lee; Duncan J Macfarlane; Sharron S K Leung; Ester Cerin; Wynnie Y Y Chan; Ivy P F Leung; Sharon H S Lam; Aliki J Taylor; Kar-keung Cheng Journal: BMJ Date: 2012-01-30
Authors: Emily A Rosenthal; Pei-Shu Ho; Galen O Joe; Sandra A Mitchell; Susan Booher; Steven Z Pavletic; Kristin Baird; Edward W Cowen; Leora E Comis Journal: Support Care Cancer Date: 2019-12-06 Impact factor: 3.603
Authors: Shaza Abo; Selina M Parry; David Ritchie; Gabriella Sgro; Dominic Truong; Linda Denehy; Catherine L Granger Journal: Support Care Cancer Date: 2022-03-16 Impact factor: 3.359
Authors: Hayley T Dillon; Nicholas J Saner; Tegan Ilsley; David Kliman; Andrew Spencer; Sharon Avery; David W Dunstan; Robin M Daly; Steve F Fraser; Neville Owen; Brigid M Lynch; Bronwyn A Kingwell; Andre La Gerche; Erin J Howden Journal: BMC Cancer Date: 2022-08-17 Impact factor: 4.638
Authors: Mira Parisek; Julika Loss; Ernst Holler; Anna Barata; Daniela Weber; Matthias Edinger; Daniel Wolff; Helene Schoemans; Anne Herrmann Journal: Front Public Health Date: 2021-07-01
Authors: Shaza Abo; David Ritchie; Linda Denehy; Yvonne Panek-Hudson; Louis Irving; Catherine L Granger Journal: Bone Marrow Transplant Date: 2021-07-16 Impact factor: 5.174